4.8 Article

Rhinitis and onset of asthma: a longitudinal population-based study

Journal

LANCET
Volume 372, Issue 9643, Pages 1049-1057

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(08)61446-4

Keywords

-

Funding

  1. Educational Grant
  2. UCB Institute
  3. Agence Nationale de la Recherche (ANR-SEST)
  4. Institut National de la Sante et de la Recherche Medicale-Assistatice Publique/Hopitaux de Paris
  5. European Commission
  6. Fondo de Investigaciones Santarias [97/0035-01, 99/0034-01, 99/0034-02]
  7. Hospital Universitario de Albacete
  8. Consejeria de Sanidad
  9. FWO (Fund for Scientific Research)-Flanders Belgium [G.0402.00]
  10. University of Antwerp
  11. Flemish Health Ministry
  12. SEPAR
  13. Public Health Service [ROI HL62633-01]
  14. CIRIT [1999SGR 00241]
  15. Swiss National Science Foundation [4026-28099]
  16. Swiss Federal Office for Education Science
  17. Swiss National Accident Insurance Fund (SUVA)
  18. Norwegian Research Council
  19. Norwegian Asthma & Allergy Association (NAAF)
  20. Glaxo Wellcome AS
  21. Norway Research Fund
  22. Institut Pneumologique d'Aquitaine
  23. GSF-National Research Centre for Environment Health
  24. Deutsche Forschungsgemeinschaft [FR 1526/1-1, MA 711/4-1]
  25. Basque Health Dept
  26. Swedish Heart Lung Foundation
  27. Swedish Foundation for Health Care Sciences & Allergy Reserch
  28. Swedish Asthma & Allergy Foundation
  29. Swedish Cancer & Allergy Foundation
  30. Programme Hospitalier de Recherche Clinique-DRC de Grenoble 2000 [2610]
  31. Ministry of Health, Direction de la Recherche Clinique
  32. Ministere de l'Emploi et de la Solidarite
  33. Direction Generale de la Saute
  34. CHU de Grenoble
  35. Comite des Maladies Respiratoires de l'lsere, Hamburg
  36. GSF-National Reasearch Centre for Environment Health
  37. Asthma UK (formerly known as National Asthma Campaign)
  38. Aventis (France)
  39. Direction Regionale des Affaires Sanitaires et Sociales Languedoc-Roussillon
  40. UCB-Pharma (France)
  41. Glaxo France
  42. Center of Clinical Investigations (CIC) of Bichat Teaching Hospital, Paris
  43. GlaxoSmithKline Italy
  44. Italian Ministry of University and Scientific and Technological Research (MURST)
  45. American Lung Association of Oregon
  46. Northwest Health Foundation
  47. Collins Foundation
  48. Merck Pharmaceutical
  49. Icelandic Research Counci
  50. Icelandic University Hospital Fund
  51. Estonian Science Foundation
  52. ASL 4 Regione Piemonte (Italy)
  53. AO CTO/ICORMA Regione Piemonte (Italy)
  54. Ministero dell' Universita e della Ricerca Scientifica (Italy)
  55. Glaxo Wellcome spa (Verona, Italy)
  56. Swedish Foundation for Health Care Sciences & Allergy Research
  57. University of Verona
  58. National Fund for Scientific Research
  59. Ministere de la Sante Glaxo France
  60. Insitut Pneumologique d'Aquitaine
  61. CNMATS
  62. CNMRT [901MR/10, 91AF/6]
  63. Ministre delegue de la sante
  64. RNSP, France
  65. GSF
  66. Bundesminister fur Forschung und Technologie, Bonn, Germany
  67. Ministero dell'Universita e della Ricerca Scientifica e Tecnologica
  68. CNR
  69. Regione Veneto grant [RSF n. 381/05.93]
  70. Norwegian Research Council [101422/310]
  71. Dutch Ministry of Wellbeing
  72. Public Health and Culture, Netherlands
  73. Ministero, Sanidad y Consumo FIS [#91/0016060/00E-05E, #93/0393]
  74. Hospital General de Albacete
  75. Hospital General Juan Ramon Jimenenz
  76. Consejeria de Sanidad Principado de Asturias, Spain
  77. The Swedish Medical Research Council
  78. Swedish Association against Asthma and Allergy
  79. National Asthma Campaign
  80. British Lung Foundation
  81. Department of Health
  82. South Thames Regional Health Authority, UK
  83. United States Department of Health, Education and Welfare Public Health Service [#2 S07 RR05521-28]

Ask authors/readers for more resources

Background A close relation between asthma and allergic rhinitis has been reported by several epidemiological and clinical studies. However, the nature of this relation remains unclear. We used the follow-up data from the European Community Respiratory Health Survey to investigate the onset of asthma in patients with allergic and non-allergic rhinitis during an 8 . 8-year period. Methods We did a longitudinal population-based study, which included 29 centres (14 countries) mostly in western Europe. Frequency of asthma was studied in 6461 participants, aged 20-44 years, without asthma at baseline. incident asthma was defined as reporting ever having had asthma confirmed by a physician between the two surveys. Atopy was defined as a positive skin-prick test to mites, cat, Alternaria, Cladosporium, grass, birch, Parietaria, olive, or 44 ragweed. Participants were classified into four groups at baseline: controls (no atopy, no rhinitis; n=3163), atopy only (atopy, no rhinitis; n=704), non-allergic rhinitis (rhinitis, no atopy; n=1377), and allergic rhinitis (atopy+rhinitis; 49 n=1217). Cox proportional hazards models were used to study asthma onset in the four groups. Findings The 8.8-year cumulative incidence of asthma was 2.2% (140 events), and was different in the four groups (1 . 1% (36), 1.9% (13), 3.1% (42), and 4.0% (49), respectively; p<0 . 0001). After controlling for country, sex, baseline age, body-mass index, forced expiratory volume in 1 s (FEV1), log total IgE, family history of asthma, and smoking, the adjusted relative risk for asthma was 1.63 (95% CI 0.82-3.24) for atopy only, 2.71 (1.64-4.46) for non-allergic rhinitis, and 3.53 (2.11-5.91) for allergic rhinitis. Only allergic rhinitis with sensitisation to mite was associated with increased risk of asthma independently of other allergens (2.79 [1.57-4.96]). Interpretation Rhinitis, even in the absence of atopy, is a powerful predictor of adult-onset asthma Funding UCB Institute of Allergy and Agence Nationale de la Recherche.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available